Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
MeSH Number(s)
E02.183.750.500
E02.319.077.500
E02.319.310.037
Concept/Terms
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Drug Combinations, Antineoplastic
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
- Combined Antineoplastic Agents
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Combined Chemotherapy Regimens
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Chemotherapy Protocols, Antineoplastic
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 39 | 31 | 70 |
1994 | 43 | 17 | 60 |
1995 | 39 | 17 | 56 |
1996 | 55 | 23 | 78 |
1997 | 56 | 17 | 73 |
1998 | 70 | 23 | 93 |
1999 | 58 | 32 | 90 |
2000 | 61 | 27 | 88 |
2001 | 59 | 22 | 81 |
2002 | 69 | 32 | 101 |
2003 | 76 | 40 | 116 |
2004 | 85 | 39 | 124 |
2005 | 102 | 41 | 143 |
2006 | 111 | 55 | 166 |
2007 | 100 | 50 | 150 |
2008 | 112 | 60 | 172 |
2009 | 137 | 55 | 192 |
2010 | 150 | 54 | 204 |
2011 | 148 | 72 | 220 |
2012 | 164 | 59 | 223 |
2013 | 162 | 69 | 231 |
2014 | 196 | 98 | 294 |
2015 | 204 | 84 | 288 |
2016 | 177 | 94 | 271 |
2017 | 183 | 103 | 286 |
2018 | 235 | 77 | 312 |
2019 | 271 | 95 | 366 |
2020 | 221 | 130 | 351 |
2021 | 184 | 157 | 341 |
2022 | 43 | 224 | 267 |
2023 | 6 | 156 | 162 |
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
ASO Visual Abstract: Mutational Status is Associated with Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer. Ann Surg Oncol. 2023 Dec; 30(13):8469-8470.
-
ASO Visual Abstract: Discordant Breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy. Ann Surg Oncol. 2023 Dec; 30(13):8467-8468.
-
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. Haematologica. 2023 11 01; 108(11):2894-2912.
-
More intensive therapy has a better effect for frail parents with multiple myeloma. Blood Adv. 2023 10 24; 7(20):6275-6284.
-
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol. 2023 Nov; 24(11):1196-1205.
-
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both. Oncologist. 2023 10 03; 28(10):e977-e980.
-
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2023 10 02; 29(19):3882-3891.
-
The nephrotoxicity of bortezomib: did we miss a complication after 20 years of use and multiple landmark trials? Nephrol Dial Transplant. 2023 09 29; 38(10):2099-2104.
-
Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits. Cancer Cell. 2023 10 09; 41(10):1696-1698.
-
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R. Blood Adv. 2023 09 26; 7(18):5320-5324.